Sir Harry Burns, the Chief Medical Officer for Scotland, announced on 22 March that Scotland will conduct a major screening trial for lung cancer using EarlyCDT-Lung – a simple blood test that detects cancer at its earliest stages of development. The test has been developed by Oncimmune, a spin out company from the University of Nottingham and an industry leader in early cancer detection.
EarlyCDT-Lung has been available in the USA for more than two years and has been shown to detect early and late stage cancers in reserach studies as well as in clinical use. Initial calculations from an independent firm of health economists in Boston show that it should be highly cost effective and reduce lung cancer mortality.
Mackintosh Capital partner Mark Loosemore has an investment in Oncimmune.